Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer-Reference-Cited by-同舟云学术

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

Published:2019-12 Issue:6 Volume:76 Page:719-728
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Hoyle Alex P.,Ali Adnan,James Nicholas D.^ORCID,Cook Adrian,Parker Christopher C.,de Bono Johann S.^ORCID,Attard Gerhardt^ORCID,Chowdhury Simon,Cross William R.,Dearnaley David P.^ORCID,Brawley Christopher D.,Gilson Clare,Ingleby Fiona,Gillessen Silke^ORCID,Aebersold Daniel M.,Jones Rob J.,Matheson David,Millman Robin,Mason Malcolm D.,Ritchie Alastair W.S.,Russell Martin,Douis Hassan,Parmar Mahesh K.B.,Sydes Matthew R.^ORCID,Clarke Noel W.

Publisher

Elsevier BV

Subject

Urology

Reference25 articles.

1. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

2. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017

3. FDAC for DER. Zytiga (abiraterone acetate) plus prednisone approved for treatment of patients with metastatic high-risk castrate sensitive metastatic prostate cancer;FDA,2018

4. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit;Royston;Trials,2011

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Efficacy and Safety of Low-Dose Abiraterone With Food and Standard-Dose Abiraterone in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Analysis;Clinical Genitourinary Cancer;2024-12

2. Nanomedicines in diagnosis and treatment of prostate cancers: an updated review;Frontiers in Bioengineering and Biotechnology;2024-08-21

3. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer;European Urology;2024-08

4. Clinical efficacy of current treatments for high-volume metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis;Holistic Integrative Oncology;2024-07-22

5. Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone‐sensitive prostate cancer;The Prostate;2024-07-10